First Trust Advisors LP Buys 38,887 Shares of Regeneron Pharmaceuticals, Inc. (REGN)

First Trust Advisors LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,311 shares of the biopharmaceutical company’s stock after purchasing an additional 38,887 shares during the quarter. First Trust Advisors LP owned approximately 0.14% of Regeneron Pharmaceuticals worth $66,760,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares in the last quarter. BlackRock Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after acquiring an additional 41,406 shares during the period. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after acquiring an additional 148,962 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after acquiring an additional 29,252 shares during the period. Finally, Polen Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 7.3% during the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock worth $779,105,000 after acquiring an additional 108,413 shares during the period. Institutional investors own 67.63% of the company’s stock.

A number of analysts recently commented on REGN shares. Barclays PLC lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reiterated a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Morgan Stanley reiterated an “equal weight” rating and set a $490.00 price target (up from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. BMO Capital Markets reiterated a “market perform” rating and set a $484.00 price target (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $481.49.

In other news, Chairman P Roy Vagelos sold 10,986 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $470.17, for a total value of $5,165,287.62. Following the completion of the sale, the chairman now owns 329,543 shares of the company’s stock, valued at approximately $154,941,232.31. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,942 shares of company stock valued at $42,064,076. Corporate insiders own 10.80% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down $1.67 during mid-day trading on Friday, reaching $404.54. The company’s stock had a trading volume of 771,100 shares, compared to its average volume of 900,360. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.21 and a current ratio of 3.63. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a market capitalization of $43,525.81, a price-to-earnings ratio of 35.17, a P/E/G ratio of 1.40 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the previous year, the company posted $3.13 earnings per share. The company’s revenue was up 23.0% compared to the same quarter last year. equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.77 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “First Trust Advisors LP Buys 38,887 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/first-trust-advisors-lp-raises-stake-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

One Response

  1. Regeneron is now under 410, so all of those predictions are all wrong. Lets see how earnings go on November 8th. At 400 to 420, Regeneron is fairly priced. Suckers bought in at above 500 to 540. Long term 405 to 410 is cheap, but Wall Street is overselling bio tech right now.
    When buying return, Regeneron will hit 470 very fast. Regeneron is a strong buy at 405. At 470 just a buy. Over 500 sell it.

Leave a Reply